BERGENBIO PRESENTS DATA ON ANTI-AXL ANTIBODY TILVESTAMAB AT 32[nd] ENA SYMPOSIUM
Bergen, Norway, 14 October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that pre-clinical data on tilvestamab, the Company’s novel function blocking, humanized anti-AXL antibody, will be presented at an ePoster presentation at the virtual 32[nd] EORTC NCI AACR (ENA) Symposium. The data presented shows that tilvestamab prevents AXL mediated cell signaling in cancer cell lines, reduces cell migration and invasion and shows anti-tumor efficacy in a panel of mouse